Raymond James Archives - Page 3 of 4

Markets

Raymond James starts Skylight Health Group at OP 2; PT $2.25 (Canadian)

Raymond James initiated coverage of Skylight Health Group (TSXV:SHG) with an “outperform (2)” ranting and $2.25 (Canadian) target price. The stock closed at $1.66 on Feb. 23. Skylight operates a large and growing U.S...

February 24, 2021

Markets

Raymond James ups Protech Home Medical PT to $3 (Canadian) from $2.00

Raymond James raised its price target for Protech Home Medical (TSXV:PTQ) to $3 (Canadian) from $2.00, citing an update to its valuation methodology. The stock closed at $2.05 on Jan. 21. Protech is a provider of...

January 22, 2021

Markets

Raymond James starts Protech Home Medical at OP; PT $2 (Canadian)

Raymond James initiated coverage of Protech Home Medical (PTQ-TSXV) with an “outperform” rating and price target of $2 (Canadian). The stock closed at $1.44 on Dec. 14. Protech provides clinical respiratory equipment...

December 15, 2020

Markets

Raymond James starts Perimeter Medical Imaging at OP; PT $3 (Canadian)

Raymond James initiated coverage of Perimeter Medical Imaging AI (TSXV:PINK) with an “outperform” rating and price target of $3 (Canadian). The stock closed at $2.19 on Nov. 6. Perimeter is commercializing its Optical...

November 9, 2020

Developments

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

Analysts for Raymond James and Cowen say two posters to be presented at the European Association of Urology (EAU) virtual conference in mid-July enhance the clinical utility of Profound Medical’s (NASDAQ:PROF;...

June 11, 2020

Markets

Raymond James sees Profound Medical insulated from COVID-19 fallout

Raymond James reiterated that Profound Medical (TSX:PRN; NASDAQ:PROF) remains its “analyst current favorite” and “2020 Best Pick,” saying Profound is “particularly insulated from the current economic fallout of COVID-19...

March 12, 2020

Markets

Raymond James starts Cardiol Therapeutics at OP 2; PT $5

Raymond James launched coverage of Cardiol Therapeutics (TSX:CRDL) with an “outperform 2” rating and price target of $5 (Canadian). The stock closed $4 on Jan.23. Cardiol’s therapeutic strategy is focused around the...

January 24, 2020

Markets

Raymond James starts Profound Medical at OP; PT $4

Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...

August 26, 2019

Executive Moves

Rahul Sarugaser joins Raymond James’ life sciences research team

Rahul Sarugaser Rahul Sarugaser has joined Raymond James’ Canadian equity research team as managing director, equity analyst, healthcare, biotechnology & cannabis. Most recently, Mr. Sarugaser was an equities...

July 12, 2019

Executive Moves

Raymond James names Andrew Gitkin as co-head of health care investment banking

Raymond James named finance professional, Andrew Gitkin, as managing director and co-head of the firm’s health care investment banking practice, along side managing director, Riley Sweat.

June 7, 2019

Tag - Raymond James

Raymond James starts Skylight Health Group at OP 2; PT $2.25 (Canadian)

Raymond James ups Protech Home Medical PT to $3 (Canadian) from $2.00

Raymond James starts Protech Home Medical at OP; PT $2 (Canadian)

Raymond James starts Perimeter Medical Imaging at OP; PT $3 (Canadian)

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

Raymond James sees Profound Medical insulated from COVID-19 fallout

Raymond James starts Cardiol Therapeutics at OP 2; PT $5

Raymond James starts Profound Medical at OP; PT $4

Rahul Sarugaser joins Raymond James’ life sciences research team

Raymond James names Andrew Gitkin as co-head of health care investment banking

General

More